vs
electroCore, Inc.（ECOR）与TransMedics Group, Inc.（TMDX）财务数据对比。点击上方公司名可切换其他公司
TransMedics Group, Inc.的季度营收约是electroCore, Inc.的17.4倍（$160.8M vs $9.2M）。TransMedics Group, Inc.净利率更高（65.6% vs -32.8%，领先98.4%）。TransMedics Group, Inc.同比增速更快（32.2% vs 31.2%）。过去两年electroCore, Inc.的营收复合增速更高（30.3% vs 28.8%）
electroCore是一家总部位于美国新泽西州巴斯金里奇的医疗科技公司，于2005年由四位联合创始人创立，现任首席执行官为Daniel S. Goldberger。公司主打产品为gammaCore，是一款已实现商业化的非侵入式设备，通过迷走神经刺激发挥作用。
TransMedics Group, Inc.是一家专注于器官移植领域的医疗科技企业，核心产品器官护理系统可在运输过程中维持捐献器官的活性，提升心、肺、肝、肾移植手术的成功率，服务覆盖北美、欧洲及亚太地区的移植中心与器官获取组织。
ECOR vs TMDX — 直观对比
营收规模更大
TMDX
是对方的17.4倍
$9.2M
营收增速更快
TMDX
高出1.0%
31.2%
净利率更高
TMDX
高出98.4%
-32.8%
两年增速更快
ECOR
近两年复合增速
28.8%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $9.2M | $160.8M |
| 净利润 | $-3.0M | $105.4M |
| 毛利率 | 88.4% | 58.1% |
| 营业利润率 | -31.8% | 13.2% |
| 净利率 | -32.8% | 65.6% |
| 营收同比 | 31.2% | 32.2% |
| 净利润同比 | 6.0% | 1436.9% |
| 每股收益（稀释后） | $-0.34 | $2.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ECORTMDX
| Q4 25 | $9.2M | $160.8M | ||
| Q3 25 | $8.7M | $143.8M | ||
| Q2 25 | $7.4M | $157.4M | ||
| Q1 25 | $6.7M | $143.5M | ||
| Q4 24 | $7.0M | $121.6M | ||
| Q3 24 | $6.6M | $108.8M | ||
| Q2 24 | $6.1M | $114.3M | ||
| Q1 24 | $5.4M | $96.8M |
净利润ECORTMDX
| Q4 25 | $-3.0M | $105.4M | ||
| Q3 25 | $-3.4M | $24.3M | ||
| Q2 25 | $-3.7M | $34.9M | ||
| Q1 25 | $-3.9M | $25.7M | ||
| Q4 24 | $-3.2M | $6.9M | ||
| Q3 24 | $-2.5M | $4.2M | ||
| Q2 24 | $-2.7M | $12.2M | ||
| Q1 24 | $-3.5M | $12.2M |
毛利率ECORTMDX
| Q4 25 | 88.4% | 58.1% | ||
| Q3 25 | 86.0% | 58.8% | ||
| Q2 25 | 87.3% | 61.4% | ||
| Q1 25 | 84.9% | 61.5% | ||
| Q4 24 | 85.9% | 59.2% | ||
| Q3 24 | 83.8% | 55.9% | ||
| Q2 24 | 86.3% | 60.6% | ||
| Q1 24 | 83.7% | 61.9% |
营业利润率ECORTMDX
| Q4 25 | -31.8% | 13.2% | ||
| Q3 25 | -33.2% | 16.2% | ||
| Q2 25 | -47.5% | 23.2% | ||
| Q1 25 | -56.9% | 19.1% | ||
| Q4 24 | -43.6% | 7.1% | ||
| Q3 24 | -40.4% | 3.6% | ||
| Q2 24 | -42.2% | 10.9% | ||
| Q1 24 | -70.7% | 12.8% |
净利率ECORTMDX
| Q4 25 | -32.8% | 65.6% | ||
| Q3 25 | -39.2% | 16.9% | ||
| Q2 25 | -49.7% | 22.2% | ||
| Q1 25 | -57.4% | 17.9% | ||
| Q4 24 | -45.8% | 5.6% | ||
| Q3 24 | -38.1% | 3.9% | ||
| Q2 24 | -43.2% | 10.7% | ||
| Q1 24 | -64.4% | 12.6% |
每股收益（稀释后）ECORTMDX
| Q4 25 | $-0.34 | $2.59 | ||
| Q3 25 | $-0.40 | $0.66 | ||
| Q2 25 | $-0.44 | $0.92 | ||
| Q1 25 | $-0.47 | $0.70 | ||
| Q4 24 | $-0.37 | $0.19 | ||
| Q3 24 | $-0.31 | $0.12 | ||
| Q2 24 | $-0.38 | $0.35 | ||
| Q1 24 | $-0.53 | $0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $11.6M | — |
| 总债务越低越好 | $7.8M | — |
| 股东权益账面价值 | $-1.7M | $473.1M |
| 总资产 | $18.7M | $1.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ECORTMDX
| Q4 25 | $11.6M | — | ||
| Q3 25 | $13.0M | — | ||
| Q2 25 | $7.1M | — | ||
| Q1 25 | $7.8M | — | ||
| Q4 24 | $12.2M | — | ||
| Q3 24 | $12.9M | $330.1M | ||
| Q2 24 | $14.2M | $362.8M | ||
| Q1 24 | $7.8M | $350.2M |
总债务ECORTMDX
| Q4 25 | $7.8M | — | ||
| Q3 25 | $7.8M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ECORTMDX
| Q4 25 | $-1.7M | $473.1M | ||
| Q3 25 | $-1.1M | $355.2M | ||
| Q2 25 | $1.1M | $318.1M | ||
| Q1 25 | $4.4M | $266.3M | ||
| Q4 24 | $7.5M | $228.6M | ||
| Q3 24 | $9.5M | $209.9M | ||
| Q2 24 | $11.5M | $189.9M | ||
| Q1 24 | $4.5M | $159.5M |
总资产ECORTMDX
| Q4 25 | $18.7M | $1.1B | ||
| Q3 25 | $21.4M | $946.0M | ||
| Q2 25 | $14.6M | $890.5M | ||
| Q1 25 | $16.0M | $837.5M | ||
| Q4 24 | $20.5M | $804.1M | ||
| Q3 24 | $21.0M | $785.6M | ||
| Q2 24 | $22.4M | $758.6M | ||
| Q1 24 | $13.9M | $723.8M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.5M | $34.5M |
| 自由现金流经营现金流 - 资本支出 | — | $19.0M |
| 自由现金流率自由现金流/营收 | — | 11.8% |
| 资本支出强度资本支出/营收 | 0.0% | 9.7% |
| 现金转化率经营现金流/净利润 | — | 0.33× |
| 过去12个月自由现金流最近4个季度 | — | $133.6M |
8季度趋势，按日历期对齐
经营现金流ECORTMDX
| Q4 25 | $-1.5M | $34.5M | ||
| Q3 25 | $-1.7M | $69.6M | ||
| Q2 25 | $-623.0K | $91.6M | ||
| Q1 25 | $-4.4M | $-2.9M | ||
| Q4 24 | $-1.3M | $19.7M | ||
| Q3 24 | $-1.4M | $6.9M | ||
| Q2 24 | $-1.8M | $25.7M | ||
| Q1 24 | $-2.6M | $-3.4M |
自由现金流ECORTMDX
| Q4 25 | — | $19.0M | ||
| Q3 25 | $-1.7M | $61.9M | ||
| Q2 25 | $-648.0K | $82.5M | ||
| Q1 25 | $-4.4M | $-29.9M | ||
| Q4 24 | — | $6.1M | ||
| Q3 24 | — | $-41.3M | ||
| Q2 24 | — | $2.0M | ||
| Q1 24 | — | $-47.6M |
自由现金流率ECORTMDX
| Q4 25 | — | 11.8% | ||
| Q3 25 | -19.3% | 43.1% | ||
| Q2 25 | -8.8% | 52.4% | ||
| Q1 25 | -65.4% | -20.8% | ||
| Q4 24 | — | 5.0% | ||
| Q3 24 | — | -38.0% | ||
| Q2 24 | — | 1.7% | ||
| Q1 24 | — | -49.2% |
资本支出强度ECORTMDX
| Q4 25 | 0.0% | 9.7% | ||
| Q3 25 | 0.0% | 5.3% | ||
| Q2 25 | 0.3% | 5.8% | ||
| Q1 25 | 0.6% | 18.8% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | — | 44.3% | ||
| Q2 24 | — | 20.8% | ||
| Q1 24 | — | 45.6% |
现金转化率ECORTMDX
| Q4 25 | — | 0.33× | ||
| Q3 25 | — | 2.86× | ||
| Q2 25 | — | 2.62× | ||
| Q1 25 | — | -0.11× | ||
| Q4 24 | — | 2.87× | ||
| Q3 24 | — | 1.63× | ||
| Q2 24 | — | 2.11× | ||
| Q1 24 | — | -0.28× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ECOR
暂无分部数据
TMDX
| Liver Product | $127.0M | 79% |
| Heart Product | $26.0M | 16% |
| Other | $5.9M | 4% |
| Lung Product | $1.9M | 1% |
